Trials / Completed
CompletedNCT02368652
A Study to Evaluate the Efficacy and Safety of Amlodipine Besylate and Candesartan Cilexetil in Essential Hypertension Patient Who Are Not Adequately Controlled With Candesartan Cilexetil Monotherapy
A Randomized, Double-blind, Multi-center, Phase III Clinical Trial to Evaluate the Antihypertensive Efficacy and Safety of Amlodipine Besylate and Candesartan Cilexetil Combination in Patients With Essential Hypertension Who Are Not Adequately Controlled With Candesartan Cilexetil Monotherapy
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 181 (actual)
- Sponsor
- HK inno.N Corporation · Industry
- Sex
- All
- Age
- 19 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
Compare the safety and efficacy of amlodipine besylate and candesartan cilexetil combination therapy on patients of essential hypertension who are not properly controlled by candesartan cilexetil monotherapy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Candesartan cilexetil 16mg | Daily oral administration for 8 weeks |
| DRUG | Amlodipine 10mg, Candesartan cilexetil 16mg | Daily oral administration for 8 weeks |
Timeline
- Start date
- 2014-12-01
- Primary completion
- 2015-11-01
- Completion
- 2015-11-01
- First posted
- 2015-02-23
- Last updated
- 2023-05-06
Locations
19 sites across 1 country: South Korea
Source: ClinicalTrials.gov record NCT02368652. Inclusion in this directory is not an endorsement.